$LXEO News

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Lexeo Therapeutics To Reveal Multiple Presentations At The 29th ASGCT Annual Meeting Taking Place May 11-15, 2026 In Boston, MA

Will Lexeo Therapeutics (NASDAQ:LXEO) Spend Its Cash Wisely?

Lexeo Therapeutics Q4 EPS $(0.27) Beats $(0.34) Estimate

Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference

Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference

Lexeo Therapeutics Details FDA Path for LX2006, Highlights LVMI Gains at Guggenheim Biotech Summit

Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February

H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

Lexeo Therapeutics Appoints José Manuel Otero As COO, Effective Immediately

Lexeo Therapeutics Appoints José Manuel Otero As COO, Effective Immediately

Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target

HC Wainwright & Co. Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $10

Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy - Slideshow